Galantamine: Difference between revisions
From SEHK Wiki
| Line 22: | Line 22: | ||
|P1S1S3 | |P1S1S3 | ||
|} | |} | ||
==Mechanism of Action== | |||
Acetylcholinesterase inhibiting drug | |||
==Dosage== | |||
By Oral: initially 4 mg twice daily for 4 weeks increased to 8 mg twice daily for 4 weeks; maintenance 8-12 mg twice daily according to response and tolerance. | |||
A modified-release preparation is also available for once-daily use. | |||
Clinical benefit should be assessed on a regular basis. | |||
Reductions in dose may be necessary in patients with hepatic or renal impairment. | |||
Revision as of 23:38, 29 September 2020
Introduction
Galantamine Hydrobromide, is a reversible inhibitor of acetylcholinesterase. It also has an intrinsic action on nicotinic receptors. It is used for the treatment of mild to moderate dementia in Alzheimer’s disease.
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Galantamine HBR Prolonged Release Cap 8mg | GALA04 | P1S1S3 |
| Galantamine HBR Prolonged Release Cap 16mg | GALA05 | P1S1S3 |
| Galantamine HBR Prolonged Release Cap 24mg | GALA06 | P1S1S3 |
Mechanism of Action
Acetylcholinesterase inhibiting drug
Dosage
By Oral: initially 4 mg twice daily for 4 weeks increased to 8 mg twice daily for 4 weeks; maintenance 8-12 mg twice daily according to response and tolerance. A modified-release preparation is also available for once-daily use. Clinical benefit should be assessed on a regular basis. Reductions in dose may be necessary in patients with hepatic or renal impairment.
